Aldeyra Therapeutics, Inc. (ALDX)

NASDAQ: ALDX · IEX Real-Time Price · USD
3.440
-0.150 (-4.18%)
At close: Feb 20, 2024, 4:00 PM
3.410
-0.030 (-0.87%)
After-hours: Feb 20, 2024, 7:58 PM EST
-4.18%
Market Cap 202.35M
Revenue (ttm) n/a
Net Income (ttm) -45.69M
Shares Out 58.82M
EPS (ttm) -0.78
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 414,459
Open 3.510
Previous Close 3.590
Day's Range 3.420 - 3.700
52-Week Range 1.420 - 11.970
Beta 1.49
Analysts Strong Buy
Price Target 11.50 (+234.3%)
Earnings Date Mar 7, 2024

About ALDX

Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases. The company also develops ADX-629, an orally administered RASP modulator for treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment primary vitreoretinal lymphoma cancer, prolife... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date May 2, 2014
Employees 12
Stock Exchange NASDAQ
Ticker Symbol ALDX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for ALDX stock is "Strong Buy." The 12-month stock price forecast is $11.5, which is an increase of 234.30% from the latest price.

Price Target
$11.5
(234.30% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Aldeyra Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company developing innovative therapies for the treatment of immune-mediated dise...

14 days ago - Business Wire

Aldeyra Therapeutics Provides Clinical and Regulatory Update and Announces Advancement of RASP Platform in Systemic and Retinal Inflammatory Diseases

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-medi...

6 weeks ago - Business Wire

Aldeyra Therapeutics Announces Statistically and Clinically Significant Improvement from Baseline in Phase 2 Clinical Trial of ADX‑629 in Patients with Atopic Dermatitis

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-medi...

2 months ago - Business Wire

Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from Phase 2 Clinical Trial of ADX-629 in Patients with Atopic Dermatitis

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced it will host a webcast and conference call on Tuesday, December 19, 2023, at 8:00 a.m. (ET) to pr...

2 months ago - Business Wire

Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Dry Eye Disease

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-medi...

3 months ago - Business Wire

Aldeyra Therapeutics Enters into Exclusive Option Agreement with AbbVie for License to Develop and Commercialize Reproxalap

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-medi...

3 months ago - Business Wire

Aldeyra Therapeutics stock plunges on heavy volume after FDA finds ‘substantive' issues with NDA for dry-eye disease treatment

Shares of Aldeyra Therapeutics Inc. ALDX, -66.43% plummeted 61.9% toward a 3 1/2-year low in very active morning trading Monday, enough to pace the Nasdaq's decliners, after the Massachusetts-based bi...

4 months ago - Market Watch

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders of a Class Action against Aldeyra Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - ALDX

NEW YORK , Sept. 29, 2023 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") (NASDAQ: ALDX), and certain...

5 months ago - PRNewsWire

FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in Aldeyra Therapeutics, Inc. with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / September 29, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Aldeyra Therapeutics, Inc. (...

5 months ago - Accesswire

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Aldeyra Therapeutics, Inc. (ALDX)

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming September 29, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of inve...

5 months ago - Business Wire

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Aldeyra Therapeutics, Inc.(ALDX) Investors of a Class Action Lawsuit and Upcoming Deadline

NEW YORK , Sept. 28, 2023 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") (NASDAQ: ALDX) of a class action securities lawsuit.

5 months ago - PRNewsWire

FINAL DEADLINE TOMORROW: The Schall Law Firm Encourages Investors in Aldeyra Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / September 28, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Aldeyra Therapeutics, Inc. (...

5 months ago - Accesswire

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Aldeyra Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of September 29, 2023 - (NASDAQ: ALDX)

NEW YORK , Sept. 27, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Aldeyra Therapeutics, Inc..

5 months ago - PRNewsWire

ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit

LOS ANGELES , Sept. 26, 2023 /PRNewswire/ --  Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit ag...

5 months ago - PRNewsWire

FINAL DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in Aldeyra Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / September 26, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Aldeyra Therapeutics, Inc. (...

5 months ago - Accesswire

DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Aldeyra Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / September 24, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Aldeyra Therapeutics, Inc. (...

5 months ago - Accesswire

FINAL DEADLINE APPROACHING: The Schall Law Firm Encourages Investors in Aldeyra Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / September 22, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Aldeyra Therapeutics, Inc. (...

5 months ago - Accesswire

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Aldeyra Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / September 21, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Aldeyra Therapeutics, Inc. (...

5 months ago - Accesswire

SHAREHOLDER ALERT: The Law Offices of Vincent Wong Remind Aldeyra Investors of a Lead Plaintiff Deadline of September 29, 2023

NEW YORK , Sept. 18, 2023 /PRNewswire/ -- Attention Aldeyra Therapeutics, Inc. ("Aldeyra") (NASDAQ: ALDX) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commenc...

5 months ago - PRNewsWire

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important September 29 Deadline in Securities Class Action - ALDX

NEW YORK , Sept. 16, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) between March 17, 2022 a...

5 months ago - PRNewsWire

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders of a Class Action against Aldeyra Therapeutics, Inc. and Certain Officers - ALDX

NEW YORK , Sept. 13, 2023 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") (NASDAQ: ALDX), and certain...

5 months ago - PRNewsWire

SHAREHOLDER ALERT: Potential Recovery for Aldeyra Therapeutics, Inc. (ALDX) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit

NEW YORK, NY / ACCESSWIRE / September 11, 2023 / If you suffered a loss on your Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) investment and want to learn about a potential recovery under the federal secur...

5 months ago - Accesswire

SHAREHOLDER ALERT: Potential Recovery for Aldeyra Therapeutics, Inc. (ALDX) Investors Affected by Stock Drop - Levi & Korsinsky Pursuing Class Action Lawsuit

NEW YORK, NY / ACCESSWIRE / September 11, 2023 / If you suffered a loss on your Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) investment and want to learn about a potential recovery under the federal secur...

5 months ago - Accesswire

ROSEN, A TOP RANKED LAW FIRM, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALDX

NEW YORK , Sept. 9, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) between March 17, 2022 an...

5 months ago - PRNewsWire

ROSEN, A LEADING LAW FIRM, Encourages Aldeyra Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - ALDX

NEW YORK , Sept. 1, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) between March 17, 2022 an...

6 months ago - PRNewsWire